| Literature DB >> 33813619 |
ShaSha Duan1,2, Si Ha1, ShuJuan Li3, YaXi Wang1, YiLu Shi1, HaiYue Zhao1, Lu Zhang1, XiaoShan Zhang4, Yong Wang5.
Abstract
OBJECTIVES: To compare cardiac function and systolic dyssynchrony of fetuses not exposed to and those exposed to maternal autoimmune antibodies using two-dimensional speckle tracking echocardiography (2DSTE).Entities:
Keywords: Anti-SSA; Anti-SSB; Antibodies; Echocardiography; Systolic dyssynchrony
Mesh:
Year: 2021 PMID: 33813619 PMCID: PMC8357746 DOI: 10.1007/s10067-021-05723-6
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980
Fig. 1Global longitudinal strain analysis of left ventricle and right ventricle from the apical four-chamber view, with a graphic representation of average strain curves displayed as function of time for each of six segments. a Left ventricle. b Right ventricle. S%, peak systolic strain
Fig. 2regional longitudinal strain analysis of left ventricle and right ventricle from the basal four-chamber view, with a graphic representation of average strain curves displayed as function of time for each of three segments. c LV free wall. d Interventricular septum. e RV free wall. S%, peak systolic strain
Fig. 3Flowchart of considered participants for study
Baseline maternal and fetal characteristics
| Parameters | Control group ( | Maternal AD group ( | |
|---|---|---|---|
| Maternal characteristics | |||
| Maternal age (y) | 31 ± 4 | 31 ± 3 | 0.933a |
| Height (cm) | 1.63 (1.60 to 1.66) | 1.65 (1.62 to 1.68) | 0.192b |
| Weight (kg) | 61.75 (57.00 to 68.50) | 63.50 (58.00 to 67.50) | 0.765b |
| BMI (kg/m2) | 24.17 ± 3.22 | 23.88 ± 2.89 | 0.757a |
| Systolic blood pressure (mm Hg) | 110 (107 to 111) | 110 (105 to 115) | 0.946b |
| Diastolic blood pressure (mm Hg) | 70 (60 to 75) | 65 (62 to 70) | 0.146b |
| Multiparity ( | 8 (24%) | 4 (22%) | 0.601c |
| History of having a baby with CHB/neonatal lupus ( | 0 (0%) | 0 (0%) | |
| Anti-SSA/Ro60 antibody positive | 0 (0%) | 18 (100%) | |
| Anti-SSB antibody positive | 0 (0%) | 3 (17%) | 0.037d |
| Anti-Ro-52 antibody positive | 0 (0%) | 9 (50%) | <0.001d |
| Methylprednisolone | 0 (0%) | 5 (28%) | 0.003d |
| Hydroxychloroquine (HCQ), 100 mg bid | 0 (0%) | 18 (100%) | |
| Fetoplacental ultrasound evaluation | |||
| Gestational age (wk) | 23.16 ± 1.09 | 23.57 ± 1.76 | 0.398a |
| Estimated fetal weight (g) | 506.03 ± 56.00 | 509.17 ± 24.44 | 0.822a |
| Umbilical artery PI | 1.13 ± 0.15 | 1.08 ± 0.10 | 0.197a |
| Middle cerebral artery PI | 1.34 (1.24 to 1.50) | 1.31 (1.23 to 1.44) | 0.525b |
| Cerebroplacental ratio | 1.20 (1.08 to 1.38) | 1.20 (1.10 to 1.35) | 0.672b |
| Ductus venosus PI | 0.55 ± 0.18 | 0.64 ± 0.15 | 0.077a |
Normally distributed variables are given as mean ± standard deviation or number (percentage). Non-normally distributed variables are given as median and interquartile range. aP-value by t-test. bP-value by Mann-Whitney U test. cP-value by chi-squared test. dP-value by Fisher’s exact probability test. AD, autoimmune disease; BMI, body mass index; CHB, complete heart block; PI, pulsatility index
Conventional fetal echocardiographic data
| Parameters | Control group ( | Maternal AD group ( | |
|---|---|---|---|
| Cardiothoracic ratio | 28.50 ± 2.96 | 29.00 ± 2.49 | 0.544a |
| Left atrial area (cm2) | 0.77 ± 0.15 | 0.83 ± 0.09 | 0.106a |
| Right atrial area (cm2) | 0.74 (0.67 to 0.82) | 0.78 (0.75 to 0.86) | 0.090b |
| Global sphericity index | 0.40 ± 0.05 | 0.38 ± 0.07 | 0.165a |
| Systolic function | |||
| Left SF (%) | 49.57 ± 7.61 | 50.28 ± 4.35 | 0.717a |
| MAPSE (mm) | 4.59 ± 0.50 | 4.78 ± 0.57 | 0.216a |
| TAPSE (mm) | 6.18 ± 0.57 | 6.37 ± 0.38 | 0.107a |
| Diastolic function | |||
| Tricuspid E/A ratio | 0.70 (0.60 to 0.74) | 0.64 (0.59 to 0.70) | 0.232b |
| Mitral E/A ratio | 0.62 ± 0.05 | 0.66 ± 0.10 | 0.155a |
| Global function | |||
| LV-MPI | 0.44 ± 0.06 | 0.45 ± 0.08 | 0.838a |
| RV-MPI | 0.46 ± 0.06 | 0.47 ± 0.06 | 0.760a |
| Mechanical PR interval (ms) | 120 (110 to 124) | 124 (119 to 128) | 0.105b |
Normally distributed variables are given as mean ± standard deviation. Non-normally distributed variables are given as median and interquartile range. aP-value by t-test. bP-value by Mann-Whitney U test. AD, autoimmune disease; LV-MPI, left ventricular myocardial performance index; MAPSE, mitral annular plane systolic excursion; RV-MPI, right ventricular myocardial performance index; SF, shortening fraction; TAPSE, tricuspid annular plane systolic excursion
Analysis of strain and dyssynchrony measurements
| Parameters | Control group ( | Maternal AD group ( | |
|---|---|---|---|
| Frame rate (frames/s) | 158 ± 16 | 158 ± 15 | 0.956a |
| Fetal heart rate (beats/min) | 142 ± 5 | 140 ± 9 | 0.396a |
| Left ventricle | |||
| Global longitudinal strain | |||
| Systolic peak (%) | −17.55 (−15.68 to −19.60) | −17.85 (−16.82 to −18.62) | 0.985b |
| Segmental longitudinal strain | |||
| FW systolic peak (%) | −17.42 ± 2.67 | −16.01 ± 3.28 | 0.100a |
| IVS systolic peak (%) | −16.01 ± 2.38 | −15.35 ± 2.92 | 0.387a |
| 1C-DYS (ms) | 19.50 (8.00 to 29.25) | 28.50 (13.50 to 39.25) | 0.042b |
| Right ventricle | |||
| Global longitudinal strain | |||
| Systolic peak (%) | −16.95 (−15.32 to −17.85) | −17.20 (−13.35 to −17.95) | 0.715b |
| Segmental longitudinal strain | |||
| FW systolic peak (%) | −17.43 ± 4.03 | −17.46 ± 3.13 | 0.976a |
| 2C-DYS (ms) | 18.00 (8.75 to 30.00) | 20.50 (7.75 to 38.50) | 0.862b |
Normally distributed variables are given as mean ± standard deviation. Non-normally distributed variables are given as median and interquartile range. aP-value by t-test. bP-value by Mann-Whitney U test. AD, autoimmune disease; 1C-DYS, one-chamber dyssynchrony; 2C-DYS, two-chamber dyssynchrony; FW, free wall; IVS, interventricular septal
Fig. 4Bland-Altman plot analysis for intra-observer and inter-observer variability for LV GLS (f, h) and 1C-DYS (g, i). LV GLSA, 1C-DYSA: measures performed by the echocardiographer A. LV GLSB, 1C-DYSB: measures performed by the echocardiographer B. LV GLS1, 1C-DYS1, LV GLS2, 1C-DYS2: first and second measure performed by the same echocardiographer
Key points |